13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03423121 (ClinicalTrials.gov) | June 19, 2018 | 12/1/2018 | A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis | A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients | Progressive Multiple Sclerosis | Drug: Tauroursodeoxycholic Acid;Drug: Placebo oral capsule | Johns Hopkins University | NULL | Recruiting | 18 Years | N/A | All | 60 | Phase 1;Phase 2 | United States |